

## **PRX-3140, a 5-HT<sub>4</sub> Partial Agonist and Sigma-1 Agonist/Antagonist, Modulates Glucocorticoid Insulin Suppression and Cortisol Levels**

**B.L. Hood<sup>1</sup>, J.P. McLaughlin<sup>2</sup>, A.R. Alleyne<sup>2</sup>, J.S. Thinschmidt<sup>2</sup>, S.W. Harden<sup>72</sup>, C.J. Frazier<sup>2</sup>  
J.D. Talton<sup>1\*</sup>**

<sup>1</sup>Alchem Laboratories Corp. / Nanopharmaceutics, Inc., Alachua FL

<sup>2</sup>Dept. of Pharmacodynamics, College of Pharmacy, Univ. of Florida, Gainesville, FL

**\*Correspondance:**

James D. Talton, Ph.D. Nanopharmaceutics, Inc. 14120 NW 126 Terrace, Alachua, FL 32615  
[jtalton@nanopharmaceutics.com](mailto:jtalton@nanopharmaceutics.com)

1 **Abstract**

2 PRX-3140 is a partial agonist to the 5-hydroxytryptamine receptor 4 (5-HT<sub>4</sub>) and a ligand for the  
3 sigma-1 (S1R) and sigma-2 (S2R) receptors. Although few publications have inferred S1R  
4 agonists/antagonists modulate blood glucose, Di et.al (2017) reported S1R deficiency in knockout  
5 mice impacted regulation of the hypothalamic-pituitary-adrenocortical (HPA) axis, with a  
6 dexamethasone-induced reduction in level of corticosterone markedly attenuated in S1R -/-  
7 knockout mice, implicating S1R in feedback response to the HPA axis. The hypothesis that S1R  
8 deficiency causes down-regulation of the glucocorticoid receptor (GR) and attenuates GR-  
9 mediated feedback inhibition of HPA axis, as well as stress response of HPA axis, suggest that the  
10 inverse, the activation of S1R under normal conditions, may modulate glucocorticoid insulin  
11 suppression (as a direct S1R-GR effect) as well as cortisol levels (producing HPA axis feedback  
12 inhibition). In the present study, coadministration of 10 μM PRX-3140 with 100 nM cortisol  
13 significantly increased insulin release (to 74.8 ng/ml, P-value <0.0001). Similar effects were  
14 observed when cells were exposed to dexamethasone (Dex), with 10 μM PRX-3140 and 10 nM  
15 Dex producing 1.87-fold significantly more insulin than 10 nM Dex alone. Daily glucose  
16 concentrations in the 14-day clinical study (NCT00384423) of PRX-3140 demonstrate a reduction  
17 for 10 mg once-daily at days 1, 7, 10, and 15. Urine free cortisol levels at 10, 30, 100 and 200 mg  
18 dose levels of PRX-3140 demonstrated a larger reduction at 7 and 14 days compared to placebo.  
19 As an agonist of S1R that acts as a chaperone of GR, PRX-3140 has demonstrated GR modulating  
20 effects in INS-1 cells and in 14-day clinical studies in healthy adults with low incidence of side  
21 effects. The results of the present study suggest that S1R activation, with PRX-3140 and NP-18-  
22 2 S1R agonists, modulates glucocorticoid insulin suppression and cortisol levels.

23

24 **KEY WORDS:** PRX-3140, glucocorticoid, cortisol, insulin, diabetes.

25

26

## 27 **1 Introduction**

28 PRX-3140 is a partial agonist to the 5-hydroxytryptamine receptor 4 (5-HT<sub>4</sub>) and a ligand for the  
29 sigma-1 (S1R) and sigma-2 (S2R) receptors that has shown promise in preclinical and clinical  
30 studies for its potential therapeutic effects in cognitive disorders, particularly Alzheimer's disease.  
31 [Johnson-2012]. By modulating S1R activity, PRX-3140 may enhance neuroprotective  
32 mechanisms, improve synaptic function, and promote neuronal health, thereby addressing  
33 neurodegenerative conditions associated with cognitive deficits [Nguyen-2017]. Studies have  
34 indicated that S1R agonists can positively influence neurotransmitter systems, including  
35 acetylcholine (ACh), which is crucial for memory and learning [van Waarde-2011]. In male Long-  
36 Evans rats, PRX-3140 intraperitoneal (IP) injection increased ACh output in the hippocampal  
37 formation under “resting” and behavioral testing conditions [Johnson-2012]. Furthermore, early  
38 clinical trials have suggested that PRX-3140 is well-tolerated and may lead to improvements in  
39 cognitive function in patients with mild to moderate Alzheimer's disease. Continued research into  
40 PRX-3140 could provide insights into its efficacy and safety, as well as its broader implications  
41 for treating cognitive impairments.

42 Three Phase 1 and two Phase 2 trials in 248 subjects have been conducted with PRX-3140 dosed  
43 orally at 5 to 250 mg daily up to two years. Most adverse events were mild to moderate in severity,  
44 and occurred primarily in the higher dose groups, including dizziness, postural dizziness,  
45 headache, abnormal dreams, nausea, diarrhea, dyspepsia, decreased appetite, and somnolence.  
46 Whereas earlier 5-HT<sub>4</sub> agonists (e.g., cisapride and tegaserod) have been associated with  
47 cardiovascular adverse events, including hERG (cardiac potassium) channel effects (QT  
48 prolongation), no cardiovascular safety concerns were reported for PRX-3140. In dose escalation  
49 studies, improvement in cognitive scores in subjects with mild Alzheimer's Disease were observed  
50 from 5 to 50 mg delivered orally once a day. In a two-week clinical study (NCT00384423), clinical  
51 laboratory measurements demonstrated modulation of glucose levels and cortisol at low doses of  
52 PRX-3140. However, post-hoc analysis was not performed to address this effect.

53 Drugs with S1R activity, such as haloperidol [Walter-2006], dextromethorphan [Marquard-2014],  
54 and pentazocine [Kavitha-1999] have been shown to have effects on glucose levels. Only a few  
55 publications have inferred that S1R agonists/antagonists modulate blood glucose levels [Paniagua-  
56 2016]. In 2017, Di et.al reported S1R deficiency in knockout mice impacted regulation of the  
57 hypothalamic-pituitary-adrenocortical (HPA) axis such that acute mild restraint stress (AMRS)  
58 induced a higher and more sustainable increase in activity of HPA axis [Di-2017]. In another  
59 experiment, Dexamethasone (Dex)-induced reduction in corticosterone levels was markedly  
60 attenuated in S1R <sup>-/-</sup> knockout mice, implicating S1R in glucocorticoid mediated feedback  
61 inhibition of the HPA axis. The hypothesis that S1R deficiency causes down-regulation of the  
62 glucocorticoid receptor (GR) and attenuates GR-mediated feedback inhibition of HPA axis, as well  
63 as stress response of HPA axis, suggest that the inverse, activation of S1R under normal conditions,  
64 may modulate glucocorticoid mediated insulin suppression (direct S1R-GR effect) as well as  
65 cortisol levels (HPA axis feedback inhibition). The present study investigated the relationship  
66 between PRX-3140 and other S1R agonists to glucocorticoid insulin suppression and cortisol

67 levels to obtain a better understanding of these direct and indirect mechanisms compared to 5-HT4  
68 activity.

## 69 **2 Materials and Methods**

### 70 **2.1 Chemicals**

71 S1R ligands 6,7-Dihydro-4-hydroxy-7-isopropyl-6-oxo-N-(3-(piperidin-1-yl)propyl)thieno[2,3-  
72 b]pyridine-5-carboxamide potassium salt (PRX-3140), N-{3-[4-(4-cyclohexylmethanesulfonyl  
73 aminobutyl)-piperazin-1-yl]phenyl} acetamide hydrochloride (NP-2), and 5-((4-(6-  
74 chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidine-1-yl)methyl)-2-fluorobenzonitrile  
75 monofumarate (NP-3) were all synthesized in-house (Alchem Laboratories Corp.). All other  
76 reagents were purchased from Sigma (St. Louis, MO) unless otherwise noted.

### 77 **2.2 Receptor Binding Assays**

78 *In vitro* radioligand competition receptor binding assays were performed to evaluate the  
79 pharmacologic profiles of PRX-3140, NP-2 and NP-3, including the S1R, S2R, a panel of  
80 serotonin receptor subtype assays (5-HT1A, 5-HT2B, and 5-HT4) and other off-target receptor  
81 subtypes. Standard receptor binding methods were employed and the majority of assays were  
82 performed using a human recombinant receptor. Where a human assay system was unavailable,  
83 receptor binding was performed in tissue from mouse, rat, guinea pig, chicken, or bovine source.

84 Human T lymphocyte Jurkat cells and guinea pig cerebral cortex were used to prepare S1R in  
85 HEPES/Tris buffer pH 7.4. PRX-3140 was incubated with 2 and 15 nM [<sup>3</sup>H] Pentazocine for 120-  
86 150 minutes. Non-specific binding is estimated in the presence of 10 μM Haloperidol. Membranes  
87 were filtered and washed, and the filters then counted in a beta scintillation counter to quantify  
88 total binding of [<sup>3</sup>H] Pentazocine, with specific binding then calculated by subtracting non-specific  
89 binding. Inhibition constants (K<sub>i</sub>) values were calculated using the equation of Cheng and Prusoff  
90 [Cheng-1973] using the observed IC<sub>50</sub> of the tested compound, the concentration of radioligand,  
91 and the historical values for the K<sub>D</sub> of the ligand (obtained experimentally at Eurofins Panlabs,  
92 Inc.) ± the standard error of the mean (SEM).

### 93 **2.3 Acute Brain Slice Preparation and Electrophysiology Studies**

94 All procedures performed on live animals as described below were reviewed and approved by the  
95 Institutional Animal Care and Use Committee at the University of Florida. Animals were deeply  
96 anesthetized using a ketamine/xylazine cocktail (0.1 ml of 10% ketamine and 0.05 ml of 2%  
97 xylazine). Brains were quickly extracted and submerged into ice-cold sucrose-laden normal  
98 artificial cerebrospinal fluid (ACSF; 206 mM sucrose, 10 mM d-glucose, 1 mM MgSO<sub>4</sub>, 2 mM  
99 KCl, 1.25 mM NaH<sub>2</sub>PO<sub>4</sub>, 1 mM CaCl<sub>2</sub>, and 25 mM NaHCO<sub>3</sub>). A VT1000s vibratome (Leica  
100 Microsystems, Buffalo Grove, IL) was used to make 300 μm coronal sections that included the  
101 nucleus accumbens (NAc). Sections were maintained at 37 °C in normal ACSF (126 mM NaCl, 11  
102 mM d-glucose, 1.5 mM MgSO<sub>4</sub>, 3 mM KCl, 1.2 mM NaH<sub>2</sub>PO<sub>4</sub>, 2.4 mM CaCl<sub>2</sub>, and 25mM  
103 NaHCO<sub>3</sub>) and subsequently equilibrated to room temperature for a minimum of 30 minutes prior  
104 to experimental use. Importantly, normal ACSF was used for incubation rather than a low-Ca<sup>2+</sup>

105 ACSF (1 mM CaCl<sub>2</sub>) as NAc MSNs (medium spiny neurons) do not regain normal AP firing  
106 function following prolonged submersion in the latter [Scala et al., 2018; Tapia et al., 2020]. All  
107 external solutions were saturated with 95% O<sub>2</sub> / 5% CO<sub>2</sub> and had a pH of 7.3.

108 Brain slices used in whole-cell patch clamp electrophysiology studies were transferred to a  
109 recording chamber continuously perfused at 2 mL/min with oxygenated ACSF maintained at 28°C.  
110 Picrotoxin (PTX, 100 μM), 6,7-dinitroquinoxaline-2,3-dione (DNWX, 20 μM), and (2R)-amino-  
111 5-phosphonovaleric acid (AP5, 40 μM) were added to ACSF to block fast synaptic currents  
112 mediated by GABA<sub>A</sub> receptors, AMPA/kainate receptors, and NMDA receptors, respectively. An  
113 Olympus BX51WI stereomicroscope supporting infrared differential interference contrast  
114 microscopy (IR-DIC) was used to visualize cells.

115 Patch pipettes (borosilicate glass capillaries 1.5 mm/0.8 mm, Sutter Instrument Company) were  
116 made using a Flaming/Brown-type pipette puller (Sutter Instrument, P-07), and had an with an  
117 open tip resistance of 4-6 MΩ when filled with a K-gluconate based internal solution that contained  
118 in mM: 2 MgCl<sub>2</sub>, 0.5 EGTA, 10 HEPES, 115 K-gluconate, 10 phosphocreatine, 4 Na<sub>2</sub>-ATP, 0.4  
119 Na<sub>3</sub>-GTP, and 5 KCl adjusted. This solution was adjusted to pH 7.25 using KOH and volume  
120 adjusted to 295 mOsm. Whole-cell recordings were made using a Multiclamp 700B amplifier,  
121 Digidata 1440A digitizer, and Clampex 10.7 software (Molecular Devices). All whole-cell data  
122 were sampled at 20 kHz and low-pass filtered at 2 kHz. Cells were identified as NAc MSNs based  
123 on location (proximity to the corpus collosum) and resting membrane potential ( $\leq -70$  mV)  
124 [Belleau and Warren, 2000; Cao et al., 2016; Willett et al., 2018; Aceto et al., 2022].

125 Analysis of electrophysiological recordings was performed with custom software written using  
126 Python 3.10 and the pyABF package [Harden, 2022] and in OriginC (OriginLab Corporation,  
127 Northampton, MA). Data presented were not corrected for the liquid junction potential. Cells were  
128 excluded from analysis that had a resting membrane potential  $> -70$  mV, that did not survive  
129 through experiment completion, or that experienced a sudden change in seal quality during  
130 recording.

131 Frequency of evoked action potentials (APs) was recorded from NAc MSNs in current-clamp  
132 configuration. Evoked APs were measured during a 4 second current injection starting from -100  
133 pA with a 20 pA increase per sweep, every 10 seconds. The resting membrane potential (RMP)  
134 was measured at the beginning of each sweep as the average voltage observed over a 3-second  
135 period with  $I = 0$ , when cells were quiescent.

#### 136 **2.4 INS-1 832/13 Rat Insulinoma Cell Line**

137 The INS-1 832/13 rat insulinoma cell line was purchased from Millipore (Temecula, CA) and  
138 cultured according to manufacturer instructions. Briefly, cells were thawed and expanded in  
139 RPMI-1640 supplemented with L-Glutamine and 25mM HEPES (Corning, Manassas, VA), 1 mM  
140 sodium pyruvate, 10 mM HEPES, 0.05 mM β-mercaptoethanol, 100 U/ml penicillin (Gibco, Grand  
141 Island, NY), 100 μg/ml streptomycin (Gibco, Grand Island, NY), and 10% EmbryoMax<sup>®</sup> ES Cell  
142 Qualified FBS at 37°C, 5% CO<sub>2</sub>, 95% humidity. After 2 days in culture, medium is exchanged  
143 with fresh medium containing G-418 (Gibco, Grand Island, New York) at 0.3 mg/ml for selective  
144 pressure. When the cells were confluent, cells were subcultured with a 1 to 6 split. For

145 subculturing, cells are detached using 0.25% Trypsin-EDTA (Gibco, Grand Island, NY). Passages  
146 13 through 27 were used for the insulin release assays.

## 147 **2.5 Insulin Secretion Assays**

148 The insulin secretion assay was based on the Millipore manufacturer insert for the INS-1 832/13  
149 cells as well as the original published paper [Hohmeier, et al, 2000]. Briefly, the INS-1 832/13  
150 cells were seeded in Costar 24-well TC plates (Corning, NY) at a cell density of  $5 \times 10^5$  cells per  
151 well using the expansion media without G418. Cultures were then incubated for 48 hours  $37^\circ\text{C}$ ,  
152 5%  $\text{CO}_2$ , 95% humidity to confluency. The media was then replaced with fresh media containing  
153 test compounds. The control wells were 2.5 mM glucose and 16.7 mM glucose with 0.1% DMSO.  
154 Plates were incubated for 18 hours ( $37^\circ\text{C}$ , 5%  $\text{CO}_2$ , 95% humidity), then wells were washed with  
155 HBSS twice (114 mmol/L NaCl, 4.7 mmol/L KCl, 1.2 mmol/L  $\text{KH}_2\text{PO}_4$ , 1.16 mmol/L  $\text{MgSO}_4$ , 20  
156 mmol/L HEPES, 2.5 mmol/L  $\text{CaCl}_2$ , 25.5 mmol/L  $\text{NaHCO}_3$ , and 0.2% bovine serum albumin, pH  
157 7.2). Next HBSS containing 2.5 mM glucose was added and incubated 1 hour ( $37^\circ\text{C}$ , 5%  $\text{CO}_2$ ,  
158 95% humidity). Cells were then washed twice with HBSS and followed by addition of HBSS with  
159 2.5 mM or 16.7 mM glucose, as well as test compounds diluted in 16.7 mM glucose. Note that  
160 DMSO was supplemented in the control wells to maintain a consistent DMSO concentration  
161 (0.1%) in all wells. After a final incubation for 2 hours ( $37^\circ\text{C}$ , 5%  $\text{CO}_2$ , 95% humidity), the  
162 supernatant was removed to measure the concentration of insulin using the ALPCO Insulin Rodent  
163 (Mouse/Rat) Chemiluminescence ELISA (ALPCO, Salem NH).

## 164 **2.6 Insulin ELISA Assay**

165 Insulin secretion was evaluated by using the ALPCO Insulin Rodent (Mouse/Rat)  
166 Chemiluminescence ELISA (ALPCO, Salem NH). Briefly, 75  $\mu\text{l}$  of working strength conjugate  
167 was dispensed to each well pre-coated with a monoclonal antibody specific to insulin. Next, 5  $\mu\text{l}$   
168 of the standards or test samples were dispensed in duplicate. The plate was sealed and incubated  
169 at room temperature for 2 hours at 700 rpm on a microplate shaker. After the incubation, the content  
170 of the wells was decanted and washed 6 times with 350  $\mu\text{l}$  of working strength wash buffer. After  
171 each wash, the plate was firmly tapped on absorbent paper to remove residual liquid. After the last  
172 wash, 100  $\mu\text{l}$  of working chemiluminescent substrate was dispensed into each well and incubated  
173 5 minutes at room temperature. Then, 80  $\mu\text{l}$  were transferred to a pureGrade™ S white plate  
174 (Brandtech Scientific, Dawsonville, GA). The plate is immediately read on the PerkinElmer  
175 Envision multi-mode plate reader in ultra-sensitive luminescent mode.

## 176 **2.7 ATPLite Cytotoxicity Assay**

177 Test compounds were diluted in DMSO. Ten nanoliters of each compound or combination of  
178 compounds were dispensed to the 6 designated test wells of a Corning 1536 well TC white plate  
179 (Corning, Kennebunk, ME) using a Labcyte/Beckman Coulter Echo 555 acoustic dispenser. For a  
180 positive control for 100% cell death, 10 nl of 10 mM MG-132 was dispensed to the positive control  
181 wells of the assay plate (final assay concentration 25  $\mu\text{M}$ ) and for the negative controls (no cell  
182 death), 10 nl of DMSO was dispensed to negative control wells of the assay plate. Next, the cells  
183 were detached from the flask, centrifuged, counted on a Cytometer T4 (Nexcelom Biosciences,  
184 Lawrence, MA) and resuspended in growth medium at a density of 400 cells per 4  $\mu\text{l}$ . Then the



185 cells were dispensed to the assay plate using the Thermo-Scientific™ Multidrop™ Combi Reagent  
186 Dispenser (4 µl of cells in each well). The plate was centrifuged at 800rpm for 15 seconds and the  
187 clear lid was replaced with a Kalypsys lid (Kalypsys, Inc. San Diego, CA) to reduce edge effects  
188 and allow the even distribution of CO<sub>2</sub> to all wells of the plate. The plate was incubated for 48  
189 hours at 37°C, 5% CO<sub>2</sub>, 95% humidity. After the incubation, 4 µl of ATPlite 1step reagent (Revvity,  
190 Waltham, MA) was dispensed into the wells using a Beckman Coulter BioRAPTR FRD. The assay  
191 plate was centrifuged at 1000rpm for 1 minute and incubated in the dark for 15 minutes at room  
192 temperature. The signal was then read on a Perkin Elmer Envision multi-mode plate reader in ultra-  
193 sensitive luminescence mode.

## 194 **2.8 Clinical Studies**

195 Data from a 14-day clinical study (NCT00384423) with PRX-3140 were analyzed (Quintiles. Inc.  
196 CRO). Each study protocol was approved by their respective investigational review board or  
197 human subjects committee. Healthy volunteers were initially enrolled with six subjects completing  
198 all treatments. Serum concentrations of PRX-3140 were determined using a validated liquid  
199 chromatography coupled with tandem mass spectrometry (LC/MS/MS) method. Serum  
200 concentration-time data were analyzed by noncompartmental methods using WinNonlin®  
201 Professional. The first cohort to evaluate the safety, tolerability and pharmacokinetics of PRX-  
202 3140 was conducted in 32 healthy adult male and female volunteers from 18 to 45 years of age.  
203 Each subject was administered an oral dose (capsules) of PRX-3140 or placebo once daily for 14  
204 days. Eight (8) subjects were randomly assigned to each of 4 sequential dosing cohorts and  
205 received either 10 mg, 30 mg, 100 mg, or 200 mg of PRX-3140 or matched placebo. If a dose  
206 regimen was found to be safe and well tolerated, then the succeeding group of 8 different subjects  
207 received the next higher dose of PRX-3140 (N = 6) or placebo (N = 2) for 14 days. Dose escalation  
208 was dependent on safety parameters (physical examination findings, vital signs, adverse events  
209 (AEs), electrocardiograms (ECGs), and clinical laboratory values including glucose and cortisol).  
210 Urine free cortisol was measured by LC-MS/MS from the first morning void urine samples  
211 collected at baseline (predose on Day 1) and predose on Days 7 and 14. Continuous glucose  
212 monitoring (CGM) was applied in a single patient with placebo compared to 10 mg PRX-3140.  
213 Clinical pharmacokinetic (PK) and pharmacodynamic (PD) sampling was performed. Subjects  
214 were monitored closely throughout the study.

## 215 **2.9 Statistical Analysis**

216 Within groups, a paired Student's t-test was used to evaluate the effect relative to the baseline  
217 mean. Across groups, an unpaired Student's t-test was used to compare data at matching time  
218 points. Differences were considered significant where  $p \leq 0.05$ .

219 For patch clamp studies, data are reported as mean ± SEM. Comparisons between groups were  
220 made with a one-way ANOVA in OriginPro (Originlab, Northampton, MA) using Sidak-Holm  
221 post-hoc tests when indicated.

222 INS-1 832/13 rat insulinoma cell line insulin release data analysis was done using GraphPad Prism  
223 Box and Whiskers plots graphed using the Tukey Boxplots analysis. The software calculates the  
224 IQR which is the inter-quartile distance (the difference between the 25th and 75th percentile). Then

225 adds the 75th percentile to 1.5 times the IQR. If this value is greater or equal to the largest value  
226 in the data set, an upper whisker is drawn at the largest value. If this value is less than the largest  
227 value, the upper whisker is set at the largest value less than the 75th percentile plus 1.5 times IQR.  
228 Any values that are greater than this value are plotted as individual points and are considered  
229 outliers for our study. For the lower whisker, the software calculates the 25th percentile minus 1.5  
230 times IQR. If this value is less than the smallest data value, the whisker is drawn at to the smallest  
231 data point. If the value is greater than the smallest data point, the whisker is set at the lowest value  
232 greater than the 25th percentile minus 1.5 times IQR. Any values that are less than this value are  
233 drawn as individual points (again, these are considered outliers for our study). The GraphPad Prism  
234 software also was used to determine P values for the Student's T-tests. The percent cell death in  
235 the cytotoxicity assays was determined using GeneData software (GeneData, Basel, Switzerland)  
236 which normalizes the data in reference to the control values.

237 Pharmacokinetic analysis was performed on patients who received active study treatment. AUC<sub>24</sub>  
238 and C<sub>max</sub> values reported as geometric mean (CV%). T<sub>1/2</sub>, glucose concentrations and urine free  
239 cortisol are expressed as arithmetic mean (SD).

## 240 **3 Results**

### 241 **3.1 5-HT and S1R Receptor Binding**

242 PRX-3140 was evaluated in a panel of serotonin receptor subtype assays to establish the selectivity  
243 for 5-HT<sub>4</sub> binding sites. PRX-3140 shows high affinity (K<sub>i</sub> = 22nM) and selectivity for 5-HT<sub>4</sub>R  
244 with more than 100-fold difference in affinities compared with all other 5-HT receptors tested.  
245 PRX-3140 also has good affinity for the S1R (K<sub>i</sub> = 79-160nM) and S2R (K<sub>i</sub> = 40-100nM) in  
246 receptor binding assays. The binding data for the 5-HT<sub>1A</sub>, 5-HT<sub>2B</sub>, 5-HT<sub>4</sub>, S1R, S2R activity is  
247 listed in Table 1.

248 NP-18-2 is a selective full agonist to the 5-HT<sub>1A</sub> and a ligand for the S1R. NP-18-2 is a high  
249 affinity (K<sub>i</sub> = 5.1-17 nM) 5-HT<sub>1A</sub> agonist in radioligand binding assays. NP-18-2 also  
250 demonstrates affinity for the S1R (K<sub>i</sub> = 100 nM) in radioligand binding assays (Table 1).

251 NP-18-3 is a selective full antagonist to the 5-HT<sub>2B</sub> receptor and a ligand for the S1R. NP-18-3 is  
252 a highly selective for 5-HT<sub>2B</sub> (K<sub>i</sub>=3.4 nM) with more than 500-fold differences in affinity for 5-  
253 HT<sub>2BR</sub> compared with all other 5-HT receptor subtypes tested except for the 5-HT<sub>1A</sub> receptor (5-  
254 HT<sub>1A</sub>, K<sub>i</sub> = 100nM). NP-18-2 also demonstrates binding to the S2R (K<sub>i</sub> = 42 nM) and S1R (K<sub>i</sub> =  
255 100 nM) in radioligand binding assays. NP-18-3 affinities for receptors are listed in Table 1.

### 256 **3.2 PRX-3140 Reduces Excitability of Medium Spiny Neurons in the Nucleus Accumbens**

257 In order to determine whether PRX-3140 directly interacts with S1R in vivo, we evaluated its  
258 ability to impact the intrinsic excitability of medium spiny neurons (MSNs) in the NAc.  
259 Specifically, we performed whole-cell patch clamp recordings from visually identified MSNs in  
260 acute tissue slices through the NAc (see methods). MSNs were injected with a series of current  
261 pulses ranging from -120 to 800 pA, and action potential frequency in response to each stimulus  
262 was measured in current clamp. Our results revealed a concentration-dependent decrease in



263 maximum action potential frequency observed in response to current injection (Figure 1, one-way  
264 ANOVA,  $F_{4, 24} = 17.6$ ,  $p < 0.0001$ ). Additional post-hoc tests revealed a significant effect of PRX-  
265 2140 vs. control at 10  $\mu\text{M}$  and 100  $\mu\text{M}$  ( $p < 0.0001$  in both cases), but not at 500 nM or 1  $\mu\text{M}$ .  
266 Overall, these effects of PRX-3140 are consistent with the reported results of other known S1R  
267 interacting compounds as described in greater detail in [Alleyne-2023].

### 268 3.3 Insulin Release Modulation by 5-HT/S1R Agonists in INS-1 832/13 Rat Insulinoma Cells

269 To examine the effect of PRX-3140 on insulin production in INS-1 832/13 cells, the cells were  
270 exposed for 18 hours to varying concentrations of PRX-3140 and then starved for 1 hour with low  
271 glucose (2.5 mM glucose). The test compound/compounds were then added back to the cells  
272 diluted in 16.7 mM glucose. The addition of 16.7 mM glucose with 10  $\mu\text{M}$  PRX-3140 or 10 nM  
273 dehydroepiandrosterone (DHEA) showed a slight increase of insulin release in these cells (138.2  
274 and 138.0 ng/ml, respectively compared to 113.8 ng/ml for 16.7 mM glucose with no compound)  
275 but the difference was not significant (Figure 2). In our studies, 10  $\mu\text{M}$  dehydroepiandrosterone  
276 sulfate (DHEA-S) slightly decreased the insulin release (107.8 ng/ml compared to 112 ng/ml  
277 glucose alone).

278 To examine the effect of endogenous glucocorticoids on insulin production in INS-1 832/13 cells,  
279 the cells were exposed to cortisol and corticosterone at physiologically relevant concentrations for  
280 18 hours, washed with HBSS twice, starved for 1 hour with low glucose (2.5 mM glucose) and  
281 then exposed to the glucocorticoids diluted in 16.7 mM glucose for 2 hours triggering the insulin  
282 release. The amount of insulin release was then determined using the insulin ELISA assay (Figure  
283 3). In these studies, 100 nM cortisol diluted in 16.7 mM glucose significantly reduced insulin  
284 release (median value 48.8 ng/ml) compared to 16.7 mM glucose alone (median value 117.3 ng/ml;  
285  $p < 0.0001$ ; Student's T-test). As expected, 500 nM cortisol had more of an effect on insulin release  
286 with a median value of 37 ng/ml. Corticosterone (100 nM in 16.7 mM glucose) also significantly  
287 decreased the insulin release giving a median value 78.2 ng/ml ( $P$  value = 0.0011). If 10  $\mu\text{M}$  PRX-  
288 3140 was co-administered with the 100 nM cortisol, the insulin release was significantly increased  
289 (median value of 74.8 ng/ml,  $P < 0.0001$ ). If 1  $\mu\text{M}$  DHEA-S was co-administered with 100 nM  
290 cortisol, there was no difference between this combination compared to 100 nM cortisol alone. If  
291 a combination of 100 nM cortisol plus 10 nM DHEA was added to the cells, the insulin release  
292 dropped to 37.0 ng/ml which is significantly different from 100 nM cortisol alone ( $P$  value =  
293 0.0015). The combination of 500 nM Cortisol plus 10 nM DHEA had a median value of 33.2 ng/ml  
294 which is statistically the same as 500 nM cortisol (30.4 ng/ml).

295 To examine the effect of a highly potent glucocorticoid, dexamethasone (Dex) was tested in INS-  
296 1 832/13 cells. As described previously, chronic exposure to the compound/compounds for 18  
297 hours was followed by starvation with 2.5 mM glucose and stimulation with 16.7 mM glucose  
298 with and without compounds. Then, insulin released was measured in the insulin ELISA. The  
299 results are shown in Figure 4. The amount of insulin produced with 10 nM Dex in the wells was  
300 52.5 ng/ml while 100 nM Dex yielded 38.6 ng/ml of insulin. If 10  $\mu\text{M}$  PRX-3140 was included  
301 with the 10 nM Dex, significantly more insulin was produced (98.3 ng/ml,  $P$  value = 0.0124).  
302 When 10  $\mu\text{M}$  PRX-3140 was combined with 100 nM Dex, the amount of insulin produced was  
303 62.6 ng/ml which was greater than the amount with 100 nM Dex alone but it was not considered

304 significant when the T-test analysis was performed. NP-18-2 released 138.15 ng/ml which was  
305 almost identical to PRX-3140 (138.20 ng/ml). However, when combined with 10 nM Dex, NP-18-  
306 2 did not recover the insulin release to the extent that PRX-3140 did (76.4 ng/ml vs 98.3 ng/ml,  
307 respectively). When NP-18-3 was dispensed to the cells, the median insulin production was 126.7  
308 ng/ml. In combination with 10 nM Dex, NP-18-3 yielded only 40.7 ng/ml which was less than 10  
309 nM Dex alone (52.4 ng/ml). However, the difference here was not significant. Cytotoxicity at 48  
310 hours in INS-1 832/13 rat insulinoma cells was dose dependent based on steroid concentration  
311 similar to published studies [Suksri-2022]. All S1R agonists alone were not cytotoxic (data not  
312 shown).

### 313 **3.4 PRX-3140 Modulates Glucocorticoid Insulin Suppression and Cortisol Levels**

314 Serum concentrations of PRX-3140 were detectable after administration of a single 5 mg dose and  
315 all other doses tested up to 16 hours and, in general, the mean serum concentrations of PRX-3140  
316 increased with ascending single doses of 5 to 250 mg. The PK data suggested that PRX-3140 was  
317 absorbed at a relatively rapid rate ( $T_{max}$  1 to 2 hours) and the exposure showed moderate to high  
318 intersubject variability median values across this dose range studied but were generally dose-  
319 proportional. The  $C_{max}$  values at the doses of 30 to 200 mg were less variable than those at the  
320 lower doses studied (5 and 10 mg). The mean half-life ( $T_{1/2}$ ) at doses of 50 to 250 mg was 8 to 14  
321 hours, respectively, suggesting the feasibility of once daily dosing. The  $C_{max}$  values at the doses  
322 of 25 to 250 mg (CVs 34-43%) were less variable than those at the lower doses studied. Following  
323 multiple oral dose administration of 10, 30, 100, or 200 mg PRX-3140 for 14 days, mean exposures  
324 ( $C_{max}$  and  $AUC_{24}$ ) of PRX-3140 appeared to increase in a dose proportional manner. Dose-  
325 related increases in the mean trough serum concentration increases were evident throughout the  
326 treatment period and appeared to reach steady state by approximately Day 7 for the 10, 30, and  
327 100 mg cohorts and Day 14 for the 200 mg PRX-3140 cohort. Non-compartmental PK parameters  
328 are presented in Table 2.

329 Daily glucose concentrations in the 14-day study at 10, 30, 100 and 200 mg dose levels of PRX-  
330 3140 demonstrate a reduction for 10 mg once-daily at days 1, 7, 10, and 15 (Figure 5). Because of  
331 the small patient number ( $n=6$  for PRX-3140 groups) and interpatient variability, this reduction  
332 was not statistically significant (Table 3.) Average daily glucose concentrations for placebo vs.  
333 10mg PRX-3140 using CGM were 125 and 108 mg/dL, respectively, demonstrating a 15.6%  
334 reduction (data not shown). Out-of-range % > 140 mg/dL showed a reduction for 10mg PRX-  
335 3140 compared to placebo (4.1% vs. 17%, respectively), demonstrating an improvement in  
336 glycemic control.

337 Urine free cortisol levels in the 14-day study at 10, 30, 100 and 200 mg dose levels of PRX-3140  
338 compared to placebo demonstrate a reduction at 7 and 14 days compared to initial Day 1 (Figure  
339 6). In particular, 10 mg PRX-3140 demonstrated a reduction from -450 vs. 159 nmol/L at Day 7  
340 and -288 vs. -57 nmol/L at Day 14 for 10mg PRX-3140 vs. placebo, respectively (Table 3).  
341 Because of the small patient number ( $n=8$ ) and interpatient variability, the reduction for placebo  
342 vs. 10 mg PRX-3140 at Days 7 and 14 were not statistically significant ( $p=0.15$  and  $0.27$ ,  
343 respectively). 100 mg PRX-3140 demonstrated a higher reduction from -674 vs. 159 nmol/L at  
344 Day 7 and -318 vs. -57 nmol/L at Day 14 for 100 mg PRX-3140 vs. placebo, respectively, but

345 baseline urine free cortisol at Day 1 was higher for 100 mg PRX-3140. 200 mg PRX-3140  
346 demonstrated a reduction from -298 vs. 159 nmol/L at Day 7 and -346 vs. -57 nmol/L at Day 14  
347 for 200 mg PRX-3140 vs. placebo, respectively, but accompanied a higher incidence of side  
348 effects. The trend for all mean PRX-3140 doses demonstrated lower cortisol levels at Day 7 and  
349 14 compared to placebo.

#### 350 **4 Discussion**

351 Direct acting medications that lower cortisol levels include ketoconazole, metyrapone, mitotane,  
352 mifepristone, osilodrostat, and pasireotide, blocking the production or binding to the GR. All of  
353 these drugs have notable side effects, including adrenal insufficiency, headache, vomiting, nausea,  
354 fatigue, and edema (swelling caused by fluid retention), and with mifepristone abortion. As an  
355 agonist of S1R that acts as a chaperone of GR, PRX-3140 has demonstrated GR modulating effects  
356 in INS-1 cells and in 14-day clinical studies in healthy adults with low incidence of side effects.

357 Since the report that S1R knock-out mice demonstrated down-regulation of GR attenuating  
358 feedback inhibition of the HPA axis [Di-2017], the potential of S1R agonists to modulate GR-  
359 mediated insulin suppression and cortisol levels became of interest. Di et al. presented *in vivo*  
360 evidence to show that S1R deficiency in CRF cells attenuates the GR-mediated feedback inhibition  
361 of the HPA axis and facilitates the stress response of the HPA axis by down-regulation of PKC  
362 signaling to suppress the GR phosphorylation. The results of the present study suggest that S1R  
363 activation, with PRX-3140 and NP-18-2 S1R agonists, modulates glucocorticoid insulin  
364 suppression and cortisol levels.

365 In receptor binding assays, PRX-3140 is highly potent ( $K_i = 22\text{nM}$ ) and selective for 5-HT<sub>4</sub>R with  
366 more than 100-fold difference in affinities compared with all other 5-HT receptors tested. PRX-  
367 3140 also displays affinity for the S1R ( $K_i = 79\text{-}160\text{nM}$ ) and S2R ( $K_i = 40\text{-}100\text{nM}$ ) in receptor  
368 binding assays. NP-18-2 is a selective agonist for the 5-HT<sub>1A</sub> with affinity for the S1R but not  
369 the S2R. NP-18-3 is a selective antagonist to the 5-HT<sub>2B</sub> and also demonstrates binding to the  
370 S2R ( $K_i = 42\text{ nM}$ ) and S1R ( $K_i = 100\text{ nM}$ ). The three compounds demonstrate selectivity for  
371 different 5-HT receptors and differential selectivity for S1R and S2R, with NP-18-2 with the  
372 highest S1R selectivity. Binding to over 50 other receptor subtypes was low and did not overlap  
373 for any one compound.

374 Receptor binding assay results cannot reflect activity, and while a cell-based assays monitoring the  
375 dissociation of the sigma-1 receptor from its chaperone protein, BiP (also known as GRP78) is  
376 used to determine activity [Yano et al., 2018], this assay is prone to variability based on conditions  
377 and S1R ligands tested that may complicate interpretation. Therefore, to confirm the S1R activity  
378 of PRX-3140, *in vitro* electrophysiology was used as a functional assay. Neuronal excitability on  
379 NAc excitability showed a dose dependent reduction in maximum evoked AP firing similar to  
380 results with the known S1R antagonist CM304 [Allyene-2023]. Notably, PRX-3140 and NP-18-2  
381 demonstrate S1R antagonist activity at high doses, but reports have also shown antagonists  
382 administered at low concentrations can produce the agonist-like effects [Maurice-2021].

383 Cortisol, an endogenous glucocorticoid hormone produced with a circadian daily rhythm, plays a  
384 critical role in the body's stress response, but prolonged elevation of cortisol levels can lead to  
385 various health issues. Cortisol is released by the adrenal cortex in response to adrenocorticotrophic  
386 hormone (ACTH), which is released by the pituitary in response to corticotropin-releasing  
387 hormone (CRH) released by the hypothalamus in response to stress. Chronic stress and high  
388 cortisol levels are associated with conditions such as obesity, hypertension, diabetes, and  
389 cardiovascular diseases [Abraham-2013]. Dehydroepiandrosterone (DHEA), proposed as the  
390 endogenous ligand for the S1R ( $K_i=15 \mu\text{M}$ ), is the most abundant circulating steroid in the human  
391 body produced in the adrenal gland and *de novo* in the central nervous system [Yabuki-2015]. After  
392 smoking a cigarette, plasma ACTH and epinephrine increase, followed by cortisol and DHEA  
393 reaching peak levels between 30 and 60 minutes after smoking [Mendelson-2005]. The increases  
394 in cortisol and DHEA were significantly correlated, and each had a similar half-life after high  
395 nicotine cigarette smoking.

396 Cortisol and DHEA interact with the S1R and can influence the expression and activity of S1R,  
397 affecting neuronal health and resilience to stress [Rennekamp-2016]. The S1R is thought to play a  
398 protective role in neuronal survival and stress response, and its modulation could offer therapeutic  
399 avenues for addressing stress-related disorders [Penke-2018]. Cortisol suppresses insulin and  
400 glucagon-like peptide-1 (GLP-1) production in the pancreas and can lead to insulin resistance  
401 [Joseph-2022]. The effect of cortisol, DHEA, and the S1R agonist PRX-3140 on insulin production  
402 was measured using the INS-1 832/13 rat insulinoma cell line. S1R agonists DHEA, PRX-3140  
403 and NP-18-2 alone moderately increased insulin release at  $10 \mu\text{M}$ , but this increase was not  
404 statistically significant.  $100 \text{ nM}$  cortisol significantly reduced insulin release ( $48.8 \text{ ng/ml}$  of insulin  
405 released compared to  $117.3 \text{ ng/ml}$  exposed to  $16.7 \text{ mM}$  glucose alone,  $P$ -value of  $<0.0001$ ). If  $10$   
406  $\mu\text{M}$  PRX-3140 was co-administered with the  $100 \text{ nM}$  cortisol, the insulin release was significantly  
407 increased ( $74.8 \text{ ng/ml}$ ,  $P$ -value  $<0.0001$ ). This improvement of insulin release was not seen with  
408 DHEA-S or DHEA co-administration. Co-administration of  $1 \mu\text{M}$  DHEA-S with  $100 \text{ nM}$  cortisol  
409 yielded no difference from  $100 \text{ nM}$  cortisol alone. Co-administration of  $10 \text{ nM}$  DHEA and  $100 \text{ nM}$   
410 cortisol drops the amount of insulin released ( $37.0 \text{ ng/ml}$ ) when compared to  $100 \text{ nM}$  cortisol alone  
411 ( $48.8 \text{ ng/ml}$ ,  $P$  value =  $0.0015$ ). Similar effects were observed when cells were exposed to  
412 dexamethasone, with  $10 \mu\text{M}$  PRX-3140 with the  $10 \text{ nM}$  Dex producing significantly more insulin  
413 than Dex alone. Dex+NP-18-2 demonstrated similar insulin release recovery to PRX-3140,  
414 however, Dex+NP-18-3 (S2R ligand) did not, potentially because the concentration tested or 5-  
415 HT2 / S2R activity.

416 5-HT1 and 5-HT4 agonists are known to interact with the HPA. The S1R is proposed as a  
417 contributor in modulation of glucocorticoid insulin suppression and cortisol levels. PRX-3140  
418 was shown to lower glucose and cortisol levels at low  $10 \text{ mg}$  daily doses up to 14 days. In a phase  
419 I clinical study NP-18-2 demonstrated lower glucose levels at low oral doses and cortisol lowering  
420 effects 1-6 hours after administration (unpublished results). PRX-3140 and NP-18-2, both S1R  
421 ligands in the  $100 \text{ nm}$  range, demonstrated similar ability to improve insulin release and lower  
422 cortisol levels at low doses but variable effects at higher doses in clinical studies suggesting a bi-  
423 phasic dose response relationship. Although 5-HT1 and 5-HT4 receptors are known to modulate

424 insulin release and cortisol, the biphasic dose response suggests that S1R activity is a factor.  
425 Further clinical studies are warranted to study these effects.

## 426 **5. Data Availability Statement**

427 The raw data supporting the conclusions of this article will be made available by the corresponding  
428 author, without undue reservation.

## 429 **6. Conflict of Interest**

430 JDT is an employee of Nanopharmaceutics, Inc., which holds rights in PRX-3140, NP-18-2 and  
431 NP-18-3.

## 432 **7. Author Contributions**

433 BH performed experiments in INS-1 832/13 rat insulinoma cells, completed data analysis,  
434 manuscript writing, and production of final figures. JM, AA, JST, SWH, and CJF performed and  
435 assisted with the in vitro electrophysiology experiments, development of software tools for data  
436 analysis and manuscript editing. JDT wrote the initial version of the manuscript, interpreted  
437 clinical data and pharmacokinetics, assisted with direction of the project and manuscript editing.

## 438 **8. Funding**

439 None.

## 440 **9. Acknowledgements**

441 Authors thank Gunther Hochhaus, Ph.D., Professor, Dept. of Pharmaceutics, College of Pharmacy,  
442 Univ. of Florida, for review.

443

444

445 .

446

<b>Ki</b>	<b>5-HT1A</b>	<b>5-HT2B</b>	<b>5-HT4</b>	<b>S1R</b>	<b>S2R</b>
PRX-3140	>5 uM	>5 uM	14.3 nM (5.4)	10.0 nM (3.3)	36.1 nM (16.1)
NP-18-2	5-11 nM	>5 uM	>5 uM	100 nM	>2 uM
NP-18-3	100 nM	3.4 nM	>5 uM	110 nM	42 nM

447

448 **Table 1: Receptor Binding affinity of PRX-3140, NP-18-2 and NP-18-3.** Binding Ki values for  
449 5-HT1A, 5HT2B, 5-HT4, S1R and S2R receptors were determined by using human recombinant  
450 receptor or tissue from mouse, rat, guinea pig, chicken, or bovine source. For PRX-3140, Ki values  
451 are reported as the geometric mean and S.E.M. based on four replicates (S.E.M. values expressed  
452 are shown in parentheses.)

453


454

455

456



457




458

459 **Figure 1: PRX-3140 reduces maximum firing rate of NAc MSNs in a concentration-**  
460 **dependent manner.** *Ex vivo* application of PRX-3140 produces a dose-dependent reduction in  
461 maximum firing rate observed in NAc MSNs in response to a transient (4 second) depolarizing  
462 current injection. Open circles are individual data points and closed circles are the mean at each  
463 concentration concentration (error bars +/- SD.) A one-way-ANOVA on these data reveals a  
464 statistically significant main effect of PRX-3140 (see results for additional details). Asterisks  
465 indicate statistical significance on pairwise comparisons from post-hoc tests.

466

467




468

469 **Figure 2: Response of INS-1 832/13 Cells to PRX-1340, DHEA and DHEA-S.** After an 18  
470 hours incubation with the test compounds, cells were washed, starved for 1 hour with 2.5 mM  
471 glucose and then exposed for 2 hours with the test compounds diluted in 16.7 mM glucose. The  
472 insulin content in the supernatant was determined by ELISA. Each condition is representative of  
473 an N of 4 (solid circles denote outliers.) Data was analyzed using GraphPad Prism using the Box  
474 and Whiskers plot.

475

476




477  
478 **Figure 3: Response of INS-1 832/13 Cells to Corticosterone, Cortisol, Cortisol with PRX-**  
479 **3140, DHEA and DHEA-S.** After an 18 hours incubation with the test compounds, cells were  
480 washed, starved for 1 hour with 2.5 mM glucose and then exposed for 2 hours with the test  
481 compounds diluted in 16.7 mM glucose. The insulin content in the supernatant was determined  
482 by ELISA. Each condition was tested at least 4 times. Data was analyzed using GraphPad Prism  
483 using the Box and Whiskers plot (solid circles denote outliers.) \*\*\*\* Comparison of 100 nM  
484 cortisol to 100nM cortisol with 10 µM PRX-3140; P<0.0001; Student's T test.

485

486

487



488

489 **Figure 4: Response of INS-1 832/13 Cells to Dexamethasone and in Combination with NP-**  
490 **18-2, NP-18-3 or PRX-3140.** After an 18 hours incubation with the test compounds, cells were  
491 washed, starved for 1 hour with 2.5 mM glucose and then exposed for 2 hours with the test  
492 compounds diluted in 16.7 mM glucose. The insulin content in the supernatant was determined  
493 by ELISA. Each condition was tested at least 4 times. Data was analyzed using GraphPad Prism  
494 using the Box and Whiskers plot (solid circles denote outliers.) \* Comparison of 10nM Dex to  
495 10 nM Dex with 10 µM PRX-3140; P=0.01; Student's T test.

496

497

498


PRX-3140 Dose	5 mg	10 mg	30 mg	50 mg	100 mg	200 mg
<u>Day 1</u>						
Tmax (h)	2.0	1.5	1.5	1.0	1.5	1.0
Cmax (ng/mL)	12.1 (62)	55 (36)	76 (56)	301.6 (43)	641 (56)	996 (38)
AUC24 (ng/mL*h)	64 (89)	159 (112)	514 (82)	1718 (156)	3766 (73)	4243 (46)
T1/2 (h)	3.7 (2.4)	4.2 (1.9)		10.3 (9.8)		
<u>Day 14 (Steady-state)</u>						
Tmax (h)		1.5	1.5		1.5	1.5
AUC24 (ng/mL*h)		533 (80)	879 (102)		5336 (47)	11850 (39)
Cmax (ng/mL)		77 (45)	149 (47)		729 (24)	1573 (20)
Cmin (ng/mL)		13.7	24.9		106.2	165.8
Cavg (ng/mL)		30.5	59.3		245.4	537.0
T1/2 (h)		12.7 (7.4)	12.7 (14.4)		10.2 (2.4)	8.6 (3.0)

499

500 **Table 2 Noncompartmental PK parameters for PRX-3140.** Serum pharmacokinetic parameters  
501 include Tmax - Time to maximum serum concentration (h) obtained directly from the observed  
502 concentration versus time data on Days 1 and 14; Cmax = Maximum serum concentration (ng/mL)  
503 during the dosing interval obtained directly from the observed concentration versus time data on  
504 Days 1 and 14; AUC24 = Area under the serum concentration-time curve from time zero until 24  
505 hours (ng·h/mL), calculated by linear trapezoidal summation; Cmin = Minimum serum  
506 concentration (ng/mL) during the dosing interval obtained directly from the observed  
507 concentration versus time data on Day 14; Cavg = Average steady-state serum concentration  
508 calculated as AUC24 divided by the dosing interval (24 h); T1/2 = Terminal half-life (h); CV =  
509 coefficient of variation; SD = standard deviation. AUC24 and Cmax values reported as geometric  
510 mean (CV%) and T1/2 expressed as arithmetic mean (SD).

511

512



513

514 **Figure 5: PRX-3140 effect on blood glucose.** All laboratory assessments were performed at the  
515 clinical site's certified laboratory utilizing that laboratory's normal ranges. Blood samples were  
516 collected at Screening, Day -2, 1, 2, 7, 10, 15 and following termination.

517

518

519



520


<u>Glucose</u>	<u>Screen</u>	<u>Day -2</u>	<u>Day 1</u>	<u>Day 2</u>	<u>Day 7</u>	<u>Day 10</u>	<u>Day 15</u>	<u>Term.</u>
Placebo	86.4 (7.3)	89.6 (8.5)	88.9 (5.0)	88.0 (3.9)	84.8 (4.5)	85.3 (5.0)	85.1 (3.9)	88.0 (5.4)
10 mg	88.5 (7.2)	90.0 (4.3)	83.1 (4.0)	89.1 (5.1)	79.5 (4.6)	79.5 (5.3)	80.4 (4.5)	87.0 (6.7)
30 mg	93.3 (4.8)	92.1 (3.3)	87.9 (4.9)	87.3 (4.5)	91.8 (3.2)	89.4 (2.7)	85.5 (2.5)	87.6 (5.8)
100 mg	92.4 (6.8)	93.0 (2.9)	88.5 (6.4)	87.0 (5.8)	85.2 (4.4)	85.8 (5.4)	89.3 (7.2)	93.0 (9.2)
200 mg	90.9 (5.4)	92.4 (5.9)	90.0 (5.6)	90.9 (4.2)	83.7 (2.5)	83.7 (2.5)	86.4 (4.7)	94.5 (1.5)
<u>Cortisol</u>	<u>Day 1</u>	<u>Day 7</u>	<u>Day 14</u>					
Placebo	522 (437)	364 (325)	466 (428)					
10 mg	578 (1090)	128 (127)	290 (392)					
30 mg	266 (297)	80 (41)	107 (28)					
100 mg	1146 (1591)	472 (513)	827 (990)					
200 mg	532 (1038)	235 (163)	186 (252)					

521

522 **Table 3 Glucose and Urine Free Cortisol levels for PRX-3140.** All laboratory assessments were  
 523 performed at the clinical site’s certified laboratory utilizing that laboratory’s normal ranges. Blood  
 524 samples were collected at Screening, Day -2, 1, 2, 7, 10, 15 and following termination shown as  
 525 mg/dL. Glucose expressed as arithmetic mean (SD). Urine Free Cortisol levels were collected pre-  
 526 dose at Day 1, 7, and 14 shown as nmol/L. Urine Free Cortisol expressed as arithmetic mean (SD).

527

528



529

530

531 **Figure 6: Urine Free Cortisol on Days 7 and 14.** Urine Free Cortisol in Subjects pre-dose on  
532 Day 1, 7 and Day 14 with oral administration of 10 mg (n=6), 30 mg (n=6), 100 mg (n=6), 200 mg  
533 (n=6) PRX-03140 or Placebo (n=8) for 14 days.

534

## 535 References

- 536 1. Johnson DE, Drummond E, Grimwood S, Sawant-Basak A, Miller E, Tseng E, McDowell LL,  
537 Vanase-Frawley MA, Fisher KE, Rubitski DM, Stutzman-Engwall KJ, Nelson RT, Horner WE,  
538 Gorczyca RR, Hajos M, Siok CJ. The 5-hydroxytryptamine<sub>4</sub> receptor agonists prucalopride  
539 and PRX-03140 increase acetylcholine and histamine levels in the rat prefrontal cortex and the  
540 power of stimulated hippocampal  $\theta$  oscillations. *J Pharmacol Exp Ther*. 2012 Jun;341(3):681-  
541 91. doi: 10.1124/jpet.112.192351. Epub 2012 Mar 9. PMID: 22408061
- 542 2. Nguyen L, Lucke-Wolds BP, Mookerjee S, Kaushal N, Matsumoto RR. Sigma-1 Receptors  
543 and Neurodegenerative Diseases: Towards a Hypothesis of Sigma-1 Receptors as Amplifiers  
544 of Neurodegeneration and Neuroprotection. *Adv Exp Med Biol*. 2017;964:133–152. doi:  
545 10.1007/978-3-319-50174-1\_10
- 546 3. van Waarde AV, Ramakrishnan NK, Rybczynska AA, Elsinga PH, Ishiwata K, Nijholt IM,  
547 Luiten PG, Dierckx RA. The cholinergic system, sigma-1 receptors and cognition. *Behavioural*  
548 *Brain Research*. Volume 221, Issue 2, 10 August 2011, Pages 543-554
- 549 4. Walter RB, Hoofnagle AN, Lanum SA, Collins SJ. Acute, life-threatening hypoglycemia  
550 associated with haloperidol in a hematopoietic stem cell transplant recipient. *Bone Marrow*  
551 *Transplant*. 2006 Jan;37(1):109-10. doi: 10.1038/sj.bmt.1705187. PMID: 16247427
- 552 5. Marquard J, Otter S, Welters A, Stirban A, Fischer A, Eglinger J, Herebian D, Kletke O,  
553 Klemen MS, Stožer A, Wnendt S, Piemonti L, Köhler M, Ferrer J, Thorens B, Schliess F,  
554 Rupnik MS, Heise T, Berggren PO, Klöcker N, Meissner T, Mayatepek E, Eberhard D, Kragl  
555 M, Lammert E. Characterization of pancreatic NMDA receptors as possible drug targets for  
556 diabetes treatment. *Nat Med*. 2015 Apr;21(4):363-72. doi: 10.1038/nm.3822. Epub 2015 Mar  
557 16. PMID: 25774850
- 558 6. Kavitha J, Arumugam V, Prabakaran E. Influence of Pentazocine on Serum Lipids and Selected  
559 Enzymes of Male Wistar Rats *J. Clin. Biochem. Nutr.*, 27, 1-7, 1999.
- 560 7. Paniagua JA. Nutrition, insulin resistance and dysfunctional adipose tissue determine the  
561 different components of metabolic syndrome. *World J Diabetes*. 2016 Nov 15;7(19):483-514.  
562 doi: 10.4239/wjd.v7.i19.483. PMID: 27895819
- 563 8. Di T, Zhang S, Hong J, Zhang T, Chen L. Hyperactivity of Hypothalamic-Pituitary-Adrenal  
564 Axis Due to Dysfunction of the Hypothalamic Glucocorticoid Receptor in Sigma-1 Receptor  
565 Knockout Mice. *Front Mol Neurosci*. 2017 Sep 6;10:287. doi: 10.3389/fnmol.2017.00287.  
566 eCollection 2017. PMID: 28932185
- 567 9. Cheng YC, Prusoff WH. Relationship between the inhibition constant (KI) and the  
568 concentration of inhibitor which causes 50 per cent inhibition (I<sub>50</sub>) of an enzymatic reaction.  
569 *Biochemical Pharmacology*. Volume 22, Issue 23, 1 December 1973, Pages 3099-3108
- 570 10. Scala F et al. Environmental Enrichment and Social Isolation Mediate Neuroplasticity of  
571 Medium Spiny Neurons through the GSK3 Pathway. *Cell Reports*. 2018 Apr 10;23(2):555-  
572 567. doi: 10.1016/j.celrep.2018.03.062. PMID: 29642012
- 573 11. Tapia CM, Folorunso O, Singh AK, McDonough K, Laezza F. Effects of Deltamethrin Acute  
574 Exposure on Nav1.6 Channels and Medium Spiny Neurons of the Nucleus Accumbens.  
575 *Toxicology*. 2020 Jul;440:152488. doi: 10.1016/j.tox.2020.152488. Epub 2020 May 6. PMID:  
576 32387285

- 577 12. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S,  
578 Rueden C, Saalfeld S, Schmid B, Tinevez J-Y, White DJ, Hartenstein V, Eliceiri K, Tomancak  
579 P, Cardona A. Fiji: an open-source platform for biological-image analysis. 2012. *Nat Methods*  
580 9:676–682.
- 581 13. Belleau ML, Warren RA. Postnatal Development of Electrophysiological Properties of  
582 Nucleus Accumbens Neurons. 2000. *J Neurophysiol* 84:2204–2216.
- 583 14. Cao J, Dorris DM, Meitzen J. Neonatal Masculinization Blocks Increased Excitatory Synaptic  
584 Input in Female Rat Nucleus Accumbens Core. 2016. *Endocrinology* 157:3181–3196.
- 585 15. Willett JA, Johnson AG, Vogel AR, Patisaul HB, McGraw LA, Meitzen J. Nucleus accumbens  
586 core medium spiny neuron electrophysiological properties and partner preference behavior in  
587 the adult male prairie vole, *Microtus ochrogaster*. 2018. *J Neurophysiol* 119:1576–1588.
- 588 16. Aceto G, Nardella L, Lazzarino G, Tavazzi B, Bertozzi A, Nanni S, Colussi C, D’Ascenzo M,  
589 Grassi C. Acute restraint stress impairs histamine type 2 receptor ability to increase the  
590 excitability of medium spiny neurons in the nucleus accumbens. 2022. *Neurobiol Dis*  
591 175:105932.
- 592 17. Harden SW, pyabf 2.3.7. Available at: <https://pypi.org/project/pyabf>. 2022.
- 593 18. Marino M, Misuri L, Brogioli D. A new open source software for the calculation of the liquid  
594 junction potential between two solutions according to the stationary Nernst-Planck equation.  
595 Arxiv. arXiv:1403.3640 [physics.chem-ph] 2014.
- 596 19. Golowasch J, Thomas G, Taylor AL, Patel A, Pineda A, Khalil C, Nadim F. Membrane  
597 Capacitance Measurements Revisited: Dependence of Capacitance Value on Measurement  
598 Method in Nonisopotential Neurons. 2009. *J Neurophysiol* 102:2161–2175.
- 599 20. Cirino TJ, Harden SW, McLaughlin JP, Frazier CJ. Region-specific effects of HIV-1 Tat on  
600 intrinsic electrophysiological properties of pyramidal neurons in mouse prefrontal cortex and  
601 hippocampus. 2020. *J Neurophysiol* 123:1332–1341.
- 602 21. Shen W, Hernandez-Lopez S, Tkatch T, Held JE, Surmeier DJ. Kv1.2-Containing K<sup>+</sup> Channels  
603 Regulate Subthreshold Excitability of Striatal Medium Spiny Neurons. 2004. *J Neurophysiol*  
604 91:1337–1349.
- 605 22. Hohmeier HE, Mulder H, Chen G, Henkel-Rieger R, Prentki M, Newgard CB. Isolation of  
606 INS-1-derived cell lines with robust ATP-sensitive K<sup>+</sup> channel-dependent and -independent  
607 glucose-stimulated insulin secretion. *Diabetes*. 2000 Mar;49(3):424-30. doi:  
608 10.2337/diabetes.49.3.424. PMID: 10868964
- 609 23. Alleyne AR. A Mechanistic Interrogation of the Sigma-1 Receptor as a Potential Target for  
610 Psychostimulant Use Disorder. Dissertation. 2023. [https://original-](https://original-ufdc.uflib.ufl.edu/UFE0059777/00001)  
611 [ufdc.uflib.ufl.edu/UFE0059777/00001](https://original-ufdc.uflib.ufl.edu/UFE0059777/00001)
- 612 24. Abraham SB, Rubino D, Sinaii N, Ramsey S, Nieman LK. Cortisol, obesity and the metabolic  
613 syndrome: A cross-sectional study of obese subjects and review of the literature. *Obesity*  
614 (Silver Spring). 2013 Jan;21(1):E105–E117. doi: 10.1002/oby.20083. PMID: 23505190
- 615 25. Suksri K, Semprasert N, Limjindaporn T, Yenchitsomanus PT, Kooptiwoot S, Kooptiwut S.  
616 Cytoprotective effect of genistein against dexamethasone-induced pancreatic beta-cell  
617 apoptosis. *Sci Rep*. 2022 Jul 28;12(1):12950. doi: 10.1038/s41598-022-17372-z. PMID:  
618 35902739

- 619 26. Maurice T. Bi-phasic dose response in the preclinical and clinical developments of sigma-1  
620 receptor ligands for the treatment of neurodegenerative disorders. *Expert Opinion on Drug*  
621 *Discovery*, 16:4, 373-389, DOI: 10.1080/17460441.2021.1838483
- 622 27. Yabuki Y, Shinoda Y, Izumi H, Ikuno T, Shioda N, Fukunaga K. Dehydroepiandrosterone  
623 administration improves memory deficits following transient brain ischemia through sigma-1  
624 receptor stimulation. *Brain Res.* 2015 Oct 5;1622:102-13. doi: 10.1016/j.brainres.2015.05.006.  
625 Epub 2015 Jun 25. PMID: 26119915
- 626 28. Rennekamp AJ, Huang XP, Wang Y, Patel S, Lorello PJ, Cade L, Gonzales AP, Yeh JR,  
627 Caldarone BJ, Roth BL, Kokel D, Peterson RT. Sigma-1 receptor ligands control a switch  
628 between passive and active threat responses. *Nat Chem Biol.* 2016 May 30;12(7):552–558.  
629 doi: 10.1038/nchembio.2089. PMID: 27239788.
- 630 29. Penke B, Fülöp L, Szűcs M, Frecska E. The Role of Sigma-1 Receptor, an Intracellular  
631 Chaperone in Neurodegenerative Diseases. *Curr Neuropharmacol.* 2018 Jan;16(1):97–116.  
632 PMID: 28554311
- 633 30. Joseph AM and Janssen JL. New Insights into the Role of Insulin and Hypothalamic-Pituitary-  
634 Adrenal (HPA) Axis in the Metabolic Syndrome. *Int J Mol Sci.* 2022 Jul 25;23(15):8178. doi:  
635 10.3390/ijms23158178. PMID: 35897752
- 636 31. Yano H, Bonifazi A, Xu M, Guthrie DA, Schneck SN, Abramyan AM, Fant AD, Hong WC,  
637 Newman AH, Shi L. Pharmacological Profiling of Sigma 1 Receptor Ligands by Novel  
638 Receptor Homomer Assays. *Neuropharmacology.* 2018 Jan 31;133:264–275. doi:  
639 10.1016/j.neuropharm.2018.01.042. PMID: 29407216.